Charles River Laboratories International, Inc. Common Stock (CRL)
177.62
-4.06 (-2.23%)
NYSE · Last Trade: May 8th, 7:28 PM EDT
Detailed Quote
Previous Close
181.68
Open
182.56
Bid
91.85
Ask
177.50
Day's Range
174.07 - 183.65
52 Week Range
131.30 - 228.88
Volume
978,194
Market Cap
8.95B
PE Ratio (TTM)
-61.25
EPS (TTM)
-2.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
817,265
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on y...
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.2% year on ...
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2026. For the quarter, revenue was $995.8 million, an increase of 1.2% from $984.2 million in the first quarter of 2025.
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings this Thursday before market hours. Here’s what investors should know. C...
Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity across discovery, pharmacology, and translational studies. Researchers working in these therapeutic areas can request a streamlined quote and timeline starting this quarter to keep studies on track and data flowing.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Charles River Laboratories International, Inc. (NYSE: CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoints. There was 100 percent concordance in the No Observed Adverse Effect Level (NOAEL) across all studies, and although there was some minor endpoint-level variability between the CCG and VCG, the core study conclusions remained unchanged. Continued research with clients has been ongoing to enhance and refine models to address these variabilities. Charles River’s VCG program is guided by the Alternative Methods Advancement Project™ (AMAP), an initiative focused on reducing the use of animals in research where scientifically appropriate.
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world’s leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives.
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
